课题基金 / 基金详情

项目摘要

项目成果

NAOMI TAYLOR的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 通过基因转移治疗遗传性和获得性免疫缺陷是基因治疗最先进的领域之一。使用ZAP-70蛋白酪氨酸激酶缺陷作为范例,我们先前证明了在敲除小鼠模型中肿瘤逆转录病毒介导的造血干细胞(HSC)基因校正ZAP-70缺陷的可行性(Steinberg/大津等人,Blood,2002)。虽然这种方法已成功地用于SCID患者,我们假设,一些相关的缺点可以克服原位基因校正的T淋巴祖细胞在胸腺。在体内胸腺内转移的基因提供了一个选择性的优势,转导的前胸腺细胞应导致功能性T淋巴细胞后代的产生,允许长期的免疫重建。事实上,在胸腺内注射T细胞特异性ZAP-70表达慢病毒载体到ZAP-70-/-小鼠的胸腺中后,我们观察到小鼠亚组中成熟TCR α β胸腺细胞的长期(>12个月)分化,表明载体已整合到祖细胞中。此外,在这些小鼠中产生了表达外周ZAP-70的T细胞,显示出部分多样化的受体库并且对同种异体抗原有应答(Mendali等人,J Clin Invest,2005)。我们现在建议优化这项技术的有效性和安全性。我们将改善病毒体向胸腺的输送;特别是通过注射更高量的病毒体,重复注射,刺激胸腺细胞增殖。此外,我们将改进表达ZAP-70的慢病毒载体(i)以增强CD 4启动子的基因表达和特异性,以及(ii)包括安全措施,如HS 4绝缘子序列和HSV 1-TK自杀基因。胸腺内注射这些新方法和载体后的免疫重建和功能将与离体慢病毒介导的HSC校正后获得的结果进行比较。最终,我们将使用改进的方法和载体进行实验,以评估来自NOD/Rag-/-小鼠中ZAP-70缺陷婴儿的人CD 34+衍生细胞的T细胞分化。总而言之,从这些实验中获得的数据应该促进ZAP-70缺乏症以及其他形式的SCID患者的最佳和安全的基因治疗策略的发展。
英文摘要
DESCRIPTION (provided by applicant): The treatment of genetic and acquired immunodeficiencies by gene transfer is one of the most advanced field of gene therapy. Using the ZAP-70 protein tyrosine kinase deficiency as a paradigm, we previously demonstrated the feasibility of oncoretroviral-mediated hematopotetic stem cell (HSC) gene correction for ZAP-70-deficiency in a knock out mouse model (Steinberg/Otsu et al., Blood, 2002). While this approach has been successfully used in SCID patients, we hypothesized that some of the associated drawbacks may be overcome by in situ gene correction of T lymphoid progenitors in the thymus. In vivo intrathymic transfer of a gene providing a selective advantage for transduced prothymocytes should result in the generation of functional T lymphocyte progeny allowing long-term immune reconstitution. Indeed, following intrathymic injection of a T cell-specific ZAP-70-expressing lentiviral vector into thymi of ZAP-70-/- mice, we observed long-term (>12 month) differentiation of mature TCRap thymocytes in a subset of mice, indicating that the vector had integrated into progenitor cells. Moreover, peripheral ZAP-70-expressing T cells were generated in these mice, demonstrated a partially diversified receptor repertoire and were responsive to allo-antigens (Adjali et al., J Clin Invest, 2005). We now propose to optimize the efficacy and safety of this technology. We will improve delivery of virions to the thymus; notably, by injecting higher amounts of virions, performing repeat injections, and stimulating thymocyte proliferation. Additionally, we will improve the ZAP-70-expressing lentiviral vector (i) to enhance gene expression and specificity from the CD4 promoter, and (ii) to include safety measures such as HS4 insulator sequences and the HSV1-TK suicide gene. The immune reconstitution and function following intrathymic injections with these new methods and vectors will be compared with that obtained following ex vivo lentiviral-mediated correction of HSC. Ultimately, we will perform experiments using improved methods and vectors to assess T cell differentiation of human CD34+ derived cells from ZAP-70-deficient infants in NOD/Rag-/- mice. Altogether, the data emerging from these experiments should promote the development of an optimal and safe gene therapy strategy for patients with ZAP-70-deficiency as well as other forms of SCID.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ZAP-70 Deficiency: A model for gene therapy studies
ZAP-70 Deficiency: A model for gene therapy studies
ZAP-70 Deficiency: A model for gene therapy studies
Metabolic regulation of human erythropoiesis
  • 批准号:
    9755410
  • 项目类别:
  • 资助金额:
    $13.51万
  • 财政年份:
    --
  • 负责人:
    NAOMI TAYLOR
  • 依托单位:
海外基金